Home
HelpTest ID: F_10 Coagulation Factor X Activity Assay, Plasma
Reporting Name
Coag Factor X Assay, PUseful For
Diagnosing deficiency of coagulation factor X, congenital or acquired
Evaluating hemostatic function in liver disease
Investigation of prolonged prothrombin time or activated partial thromboplastin time
Specimen Type
Plasma Na CitOrdering Guidance
Coagulation testing is highly complex, often requiring the performance of multiple assays and correlation with clinical information. For that reason, consider ordering a Coagulation Consultation.
Necessary Information
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL Platelet-poor plasma
Collection Instructions:
1. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
2. Within 4 hours of collection, centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma into a separate plastic vial, leaving 0.25 mL in the bottom of the centrifuged vial.
4. Immediately freeze plasma (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Specimen Minimum Volume
Platelet-poor plasma: 0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma Na Cit | Frozen | 14 days |
Special Instructions
Reference Values
Adults: 70-150%
Normal, full-term newborn infants or healthy premature infants may have decreased levels (≥15-20%), which may not reach adult levels for 180 or more days postnatal.*
*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing
Day(s) Performed
Monday through Friday
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
85260
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| F_10 | Coag Factor X Assay, P | 3218-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| F_10 | Coag Factor X Assay, P | 3218-5 |
Clinical Information
Factor X is a vitamin K-dependent serine protease that is synthesized in the liver. Its biological half-life is 24 to 48 hours. Factor X participates in both intrinsic and extrinsic pathways of coagulation (final common pathway) by serving as the enzyme (factor Xa) in the prothrombinase complex.
Congenital factor X deficiency is rare. Acquired deficiency is associated with liver disease, warfarin therapy, vitamin K deficiency, systemic amyloidosis, and inhibitors (rare). Deficiency may cause prolonged prothrombin time and activated partial thromboplastin time.
Interpretation
Acquired deficiency is more common than congenital deficiency.
Homozygous individuals: <25% activity
Heterozygous individuals: 25% to 50% activity
Clinical Reference
1. Girolami A, Scandellari R, Scapin M, Vettore S. Congenital bleeding disorders of the vitamin K-dependent clotting factors. Vitam Horm. 2008;78:281-374
2. Brenner B, Kuperman AA, Watzka M, Oldenburg J. Vitamin K-dependent coagulation factors deficiency. Semin Thromb Hemost. 2009;35(4):439-446
3. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35(4):407-415
4. Girolami A, Ruzzon E, Tezza F, Scandellari R, Scapin M, Scarparo P. Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature. Haemophilia. 2008;14(2):323-328
5. Girolami A, Scarparo P, Scandellari R, Allemand E. Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation. Am J Hematol. 2008;83(8):668-671
6. Favaloro EJ, Lippi G, eds. Hemostasis and Thrombosis, Methods and Protocols. Humana Press; 2017
Report Available
1 to 3 daysMethod Name
Optical Clot-Based
Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.
mml-coagulation-disorders